First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743

A. Scherpereel, S. Antonia, Y. Bautista, F. Grossi, D. Kowalski, G. Zalcman, A. Nowak, N. Fujimoto, S. Peters, A. Tsao, A. Mansfield, S. Popat, X. Sun, B. Padilla, P. Aanur, M. Daumont, B. Bennett, M. McKenna, P. Baas

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Pages (from-to)S1441-S1441
Number of pages1
JournalAnnals of Oncology
Volume31
DOIs
Publication statusPublished - Dec 2020
EventESMO Immuno-Oncology Virtual Congress -
Duration: 9 Dec 202012 Dec 2020

Cite this